Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 240

The DOI matches its Crossref record.

A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India

Open access
Sur, Dipika, Ochiai, R. Leon, Bhattacharya, Sujit K., Ganguly, Nirmal K., Ali, Mohammad, Manna, Byomkesh, Dutta, Shanta, Donner, Allan, Kanungo, Suman, Park, Jin Kyung, Puri, Mahesh K., Kim, Deok Ryun, Dutta, Dharitri, Bhaduri, Barnali, Acosta, Camilo J., Clemens, John D.·2009·New England Journal of Medicine

Abstract

BACKGROUND: Typhoid fever remains an important cause of illness and death in the developing world. Uncertainties about the protective effect of Vi polysaccharide vaccine in children under the age of 5 years and about the vaccine's effect under programmatic conditions have inhibited its use in developing countries. METHODS: We conducted a phase 4 effectiveness trial in which slum-dwelling residents of Kolkata, India, who were 2 years of age or older were randomly assigned to receive a single dose of either Vi vaccine or inactivated hepatitis A vaccine, according to geographic clusters, with 40 clusters in each study group. The subjects were then followed for 2 years. RESULTS: A total of 37,673 subjects received a dose of a study vaccine. The mean rate of vaccine coverage was 61% for the Vi vaccine clusters and 60% for the hepatitis A vaccine clusters. Typhoid fever was diagnosed in 96 subjects in the hepatitis A vaccine group, as compared with 34 in the Vi vaccine group, with no subject having more than one episode. The level of protective effectiveness for the Vi vaccine was 61% (95% confidence interval [CI], 41 to 75; P<0.001 for the comparison with the hepatitis A vaccine group). Children who were vaccinated between the ages of 2 and 5 years had a level of protection of 80% (95% CI, 53 to 91). Among unvaccinated members of the Vi vaccine clusters, the level of protection was 44% (95% CI, 2 to 69). The overall level of protection among all residents of Vi vaccine clusters was 57% (95% CI, 37 to 71). No serious adverse events that were attributed to either vaccine were observed during the month after vaccination. CONCLUSIONS: The Vi vaccine was effective in young children and protected unvaccinated neighbors of Vi vaccinees. The potential for combined direct and indirect protection by Vi vaccine should be considered in future deliberations about introducing this vaccine in areas where typhoid fever is endemic. (ClinicalTrials.gov number, NCT00125008.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa0807521

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 240

Metadata

Authors
Sur, D., Ochiai, R. L., Bhattacharya, S. K., Ganguly, N. K., Ali, M., Manna, B., Dutta, S., Donner, A., Kanungo, S., Park, J. K., Puri, M. K., Kim, D. R., Dutta, D., Bhaduri, B., Acosta, C. J., & Clemens, J. D.
Venue
New England Journal of Medicine
Published
2009-07-23
Volume
361
Issue
4
Pages
335-344
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2140447452
Cited by
240
References
0
FWCI
29.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India. https://app.cochat.ai/papers/10.1056/nejmoa0807521
The paper
Sur, D., Ochiai, R. L., Bhattacharya, S. K., Ganguly, N. K., Ali, M., Manna, B., Dutta, S., Donner, A., Kanungo, S., Park, J. K., Puri, M. K., Kim, D. R., Dutta, D., Bhaduri, B., Acosta, C. J., & Clemens, J. D. (2009). A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India. New England Journal of Medicine. https://doi.org/10.1056/nejmoa0807521

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.